PD-1/PD-L1 inhibitors combined with Lenvatinib for advanced unresectable liver cancer as the neoadjuvant therapy: a prospective, non-randomized, phase IV study
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Lenvatinib (Primary) ; Sintilimab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 24 Oct 2023 Results ( N=137, cut off : April 10, 2023 ) evaluating Sintilimab plus lenvatinib as an conversion therapy, presented at the 48th European Society for Medical Oncology Congress.
- 26 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology